Zobrazeno 1 - 10
of 20 266
pro vyhledávání: ''
Autor:
Ulrich Gatzemeier, Michael Boyer, Paolo Paoletti, Salih Emri, Christian Manegold, Claude Denham, Nicholas J. Vogelzang, James J. Rusthoven, James T. Symanowski, Clet Niyikiza, E. Kaukel, Pierre Ruffié
Publikováno v:
Journal of Clinical Oncology. 41:2125-2133
PURPOSE Patients with malignant pleural mesothelioma, a rapidly progressing malignancy with a median survival time of 6 to 9 months, have previously responded poorly to chemotherapy. We conducted a phase III trial to determine whether treatment with
Autor:
Lajos Pusztai, Gabriel N. Hortobagyi, Bryan T. Hennessy, Massimo Cristofanilli, Chafika Mazouni, Fabrice Andre, Attila Tordai, W. Fraser Symmans, Cornelia Liedtke, Marjorie C. Green, Ana M. Gonzalez-Angulo, Kenneth R. Hess, Jaime A. Mejia
Publikováno v:
Journal of Clinical Oncology. 41:1809-1815
PURPOSE Triple-negative breast cancer (TNBC) is defined by the lack of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER-2) expression. In this study, we compared response to neoadjuvant chemotherap
Publikováno v:
Journal of Clinical Oncology. 41:1331-1338
PURPOSE Immunohistochemistry (IHC) is a newer technique for assessing the estrogen receptor (ER) status of breast cancers, with the potential to overcome many of the shortcomings associated with the traditional ligand-binding assay (LBA). The purpose
Autor:
Vieri Scotti, Beatrice Fantechi, Francesca Mazzoni, I. Stasi, Irene Pecora, Carmelo Tibaldi, Enrico Vasile, Chiara Caparello, Editta Baldini, Marianna Turrini, Lorenzo Antonuzzo, Francesca Federici, Andrea Camerini, Giulia Meoni, Daniele Pozzessere, Diana Giannarelli, Virginia Rossi, L.P. Ciccone
Publikováno v:
Anti-Cancer Agents in Medicinal Chemistry. 22:1278-1285
Background: In advanced non-small-cell lung cancer, without activating mutations and with PD-L1≥50%, Pembrolizumab monotherapy is the therapeutic standard in Europe. Objective: To evaluate retrospectively the safety and efficacy of this drug and to
Autor:
Paul Mitchell, G Rivalland, Hui Yu, Fred R. Hirsch, R. Mosher, L Churilov, K Asadi, Christopher J. Rivard, S Heynemann
Publikováno v:
Clinical Lung Cancer. 23:e90-e98
Background NaPi2b is a multi-transmembrane sodium-dependent phosphate transporter expressed at normal levels in several organs, including lung. High expression levels have been reported in various tumours including breast, thyroid, ovarian and non-sm
Autor:
Li Zhu, Shuning Ding, Ou Huang, Weiguo Chen, Yafen Li, Weilin Chen, Xiaosong Chen, Jiayi Wu, Mengdi Chen, Caijin Lin, Deyue Liu, Kunwei Shen, Lisa Andriani, Jianrong He
Publikováno v:
Clinical Breast Cancer. 22:e147-e156
BACKGROUND In human epidermal growth factor receptor 2 (HER2)-positive breast cancer, emerging evidence imply that clinical behaviors differ according to hormone receptor (HR) status. However, there is no conclusion about the relevance between estrog
Publikováno v:
Future Oncology. 18:679-690
Objective: D-dimer is correlated to the poor prognosis of non-small-cell lung cancer. The study aimed to investigate the association between plasma D-dimer and concomitant mutations in non-small-cell lung cancer. Methods: A total of 517 non-small-cel
Publikováno v:
Future Oncology
Introduction: The objective of this study was to evaluate the clinical and laboratory outcomes of solid cancer patients who were reinfected with COVID-19. Methods: Patients who were tested negative on the Coronavirus disease 2019 (COVID-19) PCR test
A Systematic Comparison of Overall Survival Between Men and Women With Triple Negative Breast Cancer
Autor:
Mohammad Muhsin Chisti, Swechchha Silwal, Geetha Krishnamoorthy, Siddhartha Yadav, Sumeet Kumar Yadav
Publikováno v:
Clinical Breast Cancer. 22:161-169
Introduction Triple-negative breast cancer (TNBC) in men is very rare. The clinical characteristics, prognostic factors, and overall survival of men with TNBC have not been characterized. Methods The study population consisted of men and women with a
Autor:
John B. A. G. Haanen, Maureen J.B. Aarts, Michel W.J.M. Wouters, Albert J. ten Tije, Astrid A M van der Veldt, Karijn P M Suijkerbuijk, Rozemarijn S. van Rijn, Alfons J.M. van den Eertwegh, Liesbeth C. de Wreede, Ellen Kapiteijn, Geke A. P. Hospers, Franchette W P J van den Berkmortel, Jacobus J.M. van der Hoeven, Gerard Vreugdenhil, Michiel C T van Zeijl, Jan-Willem B de Groot, Djura Piersma
Publikováno v:
International Journal of Cancer, 150(2), 317-326. Wiley-Liss Inc.
International Journal of Cancer, 150(2), 317-326. Wiley
International Journal of Cancer, 150(2), 317-326. WILEY
International Journal of Cancer, 150, 2, pp. 317-326
International Journal of Cancer, 150, 317-326
van Zeijl, M C T, van den Eertwegh, A J M, Wouters, M W J M, de Wreede, L C, Aarts, M J B, van den Berkmortel, F W P J, de Groot, J-W B, Hospers, G A P, Kapiteijn, E, Piersma, D, van Rijn, R S, Suijkerbuijk, K P M, ten Tije, A J, van der Veldt, A A M, Vreugdenhil, G, van der Hoeven, J J M & Haanen, J B A G 2022, ' Discontinuation of anti-PD-1 monotherapy in advanced melanoma—Outcomes of daily clinical practice ', International Journal of Cancer, vol. 150, no. 2, pp. 317-326 . https://doi.org/10.1002/ijc.33800
International Journal of Cancer, 150(2), 317-326. Wiley
International Journal of Cancer, 150(2), 317-326. WILEY
International Journal of Cancer, 150, 2, pp. 317-326
International Journal of Cancer, 150, 317-326
van Zeijl, M C T, van den Eertwegh, A J M, Wouters, M W J M, de Wreede, L C, Aarts, M J B, van den Berkmortel, F W P J, de Groot, J-W B, Hospers, G A P, Kapiteijn, E, Piersma, D, van Rijn, R S, Suijkerbuijk, K P M, ten Tije, A J, van der Veldt, A A M, Vreugdenhil, G, van der Hoeven, J J M & Haanen, J B A G 2022, ' Discontinuation of anti-PD-1 monotherapy in advanced melanoma—Outcomes of daily clinical practice ', International Journal of Cancer, vol. 150, no. 2, pp. 317-326 . https://doi.org/10.1002/ijc.33800
Contains fulltext : 287666.pdf (Publisher’s version ) (Open Access) There is no consensus on the optimal treatment duration of anti-PD-1 for advanced melanoma. The aim of our study was to gain insight into the outcomes of anti-PD-1 discontinuation,